Current partner codePEPTIDESDE
PeptideStat
Menu

Vendors

Compare pricesVendor directoryVendor reviewsDiscount codesLab tests & COAs

Research

ResearchDatabaseClinical trials

Tools

All calculatorsReconstitutionAccumulationUnit converterPeptide chemistry
NCT01977079·Not applicable·INTERVENTIONAL

Procalcitonin and Threatened Premature Delivery

CalcitoninOtherTerminated

Status

Terminated

Phase

Not applicable

Enrollment

131

Locations

1

Results

Not posted

Publications

1

Study summary

What the protocol is testing.

Among all patients hospitalized for Threatened Premature Delivery (TPD), the rate of premature birth (PB) before 37 weeks is about 42%, which reflects the inability to accurately identify patients at high risk of PB. Currently, no clinical or biological marker is recognized as the most reliable in predicting the real risk of AP in case of MAP. The purpose of this study is to improve the knowledge of predictors of preterm delivery compared with conventional blood markers by estimating serum procalcitonin according to premature delivery or not in patients hospitalized for preterm labor .

Interventions

Treatment arms and agents.

OTHER

procalcitonin

Timeline

From registration to results.

  1. First posted

    Nov 6, 2013

  2. Study start

    Dec 2013

  3. Primary completion

    Jul 2016

  4. Study completion

    Jul 2016

  5. Results posted

    Not reported

  6. Registry updated

    Nov 17, 2025

Outcomes

What the study measures.

Primary outcomes

procalcitonin rate

Time frame · up to 48 hours

Estimate serum procalcitonin according to premature or not in patients hospitalized for preterm labor.

Secondary outcomes

Not reported in the indexed record.

Eligibility

Who can take part.

Minimum age
18 Years
Maximum age
Not reported
Sex
FEMALE
Healthy volunteers
No

Inclusion Criteria: * age \> 18 year * Ongoing pregnancy with a start date of pregnancy known and confirmed by an ultrasound of the 1st Quarter performed between 10 and 14 weeks with a measurement of the crown-rump length * hospitalization for preterm labor between 24 and 36 weeks of gestation * Intact membranes, * not opposed to participate in the study Exclusion Criteria: * Pregnancy uncertain term (no early ultrasound) * Pregnancy combining a condition that can interfere with the assays performed, * Uterine malformation known * Multiple pregnancy, * Premature rupture of membranes, * Chrorio-amnionitis, * Fetal malformation known * Strapping * GB\> 15000 and CRP\> 10 mg / L, * No affiliation to a social security scheme. * Woman with a measure of legal protection

Study locations

1 registered sites.

France. Showing up to 24 locations stored in the fast local snapshot.

Centre hospitalier départemental Vendée

La Roche-sur-Yon, France

Publications

Results and literature.

PMID 29514604 ↗Ducarme G, Desroys du Roure F, Le Thuaut A, Grange J, Vital M, Dimet J. Efficacy of serum procalcitonin to predict spontaneous preterm birth in women with threatened preterm labour: a prospective observational study. BMC Pregnancy Childbirth. 2018 Mar 7;18(1):65. doi: 10.1186/s12884-018-1696-2.

Primary links

Continue at the source.

ClinicalTrials.gov ↗Search PubMed ↗Search FDA ↗Search EMA ↗

Related trials

More studies on Calcitonin.

Related PeptideStat pages

Put the record in context.

Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.

TrialsCalcitonin trial dashboard →DatabaseCalcitonin database entry →ResearchCalcitonin research guide →